Compare Regeneron Pharmaceuticals Inc (REGN) vs Toast Inc. Class A Common Stock (TOST) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $753.12, down 1.27% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 19.26, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent positive news includes a strategic expansion of its immunology alliance with Sanofi, valued up to $8 billion, and promising clinical trial data for oncology and muscle preservation therapies.

The outlook for REGN remains positive, driven by robust profitability, strategic partnerships, and a strong pipeline. Key risks include competitive pressures in the biopharma sector and reliance on key products like Eylea. With a consensus price target of $856.25 and no sell ratings from analysts, the stock presents a compelling opportunity for growth-oriented investors, though market volatility and regulatory developments warrant monitoring.

Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.

The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.